What caused SKIN.SW stock to rise after-hours on 06 Jan 2026?

The after-hours rise to CHF35.70 followed above-average volume of 2,756 shares and renewed investor focus on Cassiopea's clinical dermatology assets. No regulatory filing was listed at time of trade, so the move likely reflects positioning ahead of expected clinical or commercial updates.

How does Meyka AI rate SKIN.SW stock and what does that mean?

Meyka AI rates SKIN.SW at **61.49** (Grade B, HOLD). The grade blends sector comparison, financial growth, key metrics and consensus signals. It is informational only and not financial advice.

What price target does Meyka AI give for SKIN.SW stock?

Meyka AI's forecast model projects a 12-month base target of **CHF44.00**, implying **23.25%** upside from CHF35.70. Alternate scenarios include a bull target CHF55.00 and a bear target CHF28.00. Forecasts are projections, not guarantees.

Are there major valuation risks with SKIN.SW stock?

Yes. SKIN.SW shows negative EPS **-1.27**, a negative PE and a high price-to-book **25.63**, reflecting development-stage losses. Thin liquidity and trial outcomes present valuation and execution risks for investors.

CH Stocks

SKIN.SW CHF35.70 up 9.85% after-hours 06 Jan 2026: traders eye clinical catalysts

ByDanny Kontos January 6, 2026January 6, 2026

SKIN.SW stock surged to CHF35.70, rising 9.85% in after-hours trade on 06 Jan 2026 on a volume spike to 2,756 shares. The move pushed price above the 50-day average of CHF34.37 and flagged renewed investor interest in Cassiopea S.p.A.’s clinical dermatology pipeline. We examine what drove the trade, the stock’s valuation versus the Healthcare sector, liquidity signals and short-term price scenarios. Meyka AI, an AI-powered market analysis platform, tracks this high-volume mover for real-time alerts and model-based forecasts.